In Re: Zofran (Ondansetron) Products Liability Lit v.

Procedural entryThis page is a short order in In Re: Zofran (Ondansetron) Products Liability Lit v.. Read the opinion of the Court — 57 F.4th 327 →

Court of Appeals for the First Circuit·Decided January 12, 2023·No. 21-1517E·Errata

Opinion

United States Court of Appeals For the First Circuit

No. 21-1517

IN RE: ZOFRAN (ONDANSETRON) PRODUCTS LIABILITY LITIGATION

HEATHER PERHAM, et al.,

Plaintiffs, Appellants,

GLAXOSMITHKLINE LLC,

Defendant, Appellee,

SUN PHARMACEUTICAL INDUSTRIES LTD.; SANDOZ, INC.; PROVIDENCE HEALTH SYSTEM; NOVARTIS PHARMACEUTICALS CORP.; MCKESSON CORPORATION; DOES 1 through 100, inclusive, TEVA PHARMACEUTICAL USA; GLAXOSMITHKLINE HOLDINGS (AMERICAS) INC.,

Defendants.

ERRATA SHEET

The opinion of this Court issued on January 9, 2022, is amended as follows:

On page 3, line 24, "U.S.C.A." is replaced with "U.S.C."

Free access — add to your briefcase to read the full text and ask questions with AI

United States Court of Appeals For the First Circuit

No. 21-1517

IN RE: ZOFRAN (ONDANSETRON) PRODUCTS LIABILITY LITIGATION

HEATHER PERHAM, et al.,

Plaintiffs, Appellants,

GLAXOSMITHKLINE LLC,

Defendant, Appellee,

Defendants.

ERRATA SHEET

The opinion of this Court issued on January 9, 2022, is amended as follows:

On page 3, line 24, "U.S.C.A." is replaced with "U.S.C."

In Re: Zofran (Ondansetron) Products Liability Lit v., (1st Cir. 2023).

Pincite

In Re: Zofran (Ondansetron) Products Liability Lit v. (In Re: Zofran (Ondansetron) Products Liability Lit v.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.